Cellectar Biosciences (CLRB)


From Benzinga Pro
Recap: Cellectar Biosciences Q1 Earnings
10 May 22
Cellectar Biosciences (NASDAQ:CLRB) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Cellectar Biosciences reported in-line EPS of $-0.1 versus an estimate of $-0.1.
Cellectar Biosciences Q1 EPS $(0.10) Up From $(0.13) YoY
10 May 22
Earnings, News
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.10) per share. This is a 23.08 percent increase over losses of $(0.13) per share from the same period last year.
Cellectar Biosciences Announces DMC Review Of Pivotal Trial Of Iopofosine In Waldenstrom's Macroglobulinemia
26 Apr 22
Biotech, News, General
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced
51 Biggest Movers From Thursday
18 Apr 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.
12 Health Care Stocks Moving In Thursday's Intraday Session
14 Apr 22
Here's Why Cellectar Biosciences Shares Are Rising
21 Mar 22
Penny Stocks, Movers, Trading Ideas
Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a loss of 1
Recap: Cellectar Biosciences Q4 Earnings
21 Mar 22
Earnings, News
Cellectar Biosciences (NASDAQ:CLRB) reported its Q4 earnings results on Monday, March 21, 2022 at 08:30 AM. Here's what investors need to know about the announcement.